Insulin-like growth factor I treatment reduces clinical deficits and lesion severity in acute demyelinating experimental autoimmune encephalomyelitis
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Our goal was to test the effects of insulin-like growth factor I (IGF-I) treatment on clinical deficits, lesion number and lesion size in acute demyelinating experimental autoimmune encephalomyelitis (EAE) induced in Lewis rats with an emulsion containing guinea pig spinal cord. In this EAE model, there is severe immune-mediated demyelination, which resembles that seen in actively demyelinating MS lesions. On day 12–13 after EAE induction, a total of 23 pairs of rats with the same mild degree of tail and hind limb weakness were given either intravenous IGF-I or placebo twice daily for 8 days. The daily IGF-I dose used in the first trial was 200 μg (about 0.6 mgkg-1) and in the second and third trials was 1 mg (about 3.0 mgkg-1). IGF-I treatment reduced permeability of the blood-spinal cord barrier to Evans blue-albumin. Maximum clinical deficit scores of IGF-I-treated rats were significantly lower and treated rats recovered faster than controls. IGF-I treatment produced significant reductions in weight loss and hind limb weakness. Treatment also improved treadmill walking, stride length and climbing performance. Morphometric analysis showed that spinal cord inflammatory lesions were significantly smaller and fewer in IGF-I-treated rots. The higher IGF-I dose produced a greater reduction in clinical and pathological deficits. We conclude that IGF-I treatment promotes clinical recovery by reducing EAE-induced blood-spinal cord barrier changes and the associated immune-mediated inflammatory lesions. Our results suggest that IGF-I may be useful in treating patients with multiple sclerosis and other demyelinating diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple extracellular signals are required for long-term oligodendrocyte survival
Barres, B. A., Schmid, R., Sendnter, M., & Raff, M. C. (1993) · Development · doi:10.1242/dev.118.1.283 · Cited by 712
Komoly, S., Hudson, L. D., Webster, H. D., & Bondy, C. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1894 · Cited by 223
Self-citationOligodendrocytes in the early course of multiple sclerosis
Brück, W., Schmied, M., Suchanek, G., Brück, Y., Breitschopf, H., Poser, S., Piddlesden, S., & Lassmann, H. (1994) · Annals of Neurology · doi:10.1002/ana.410350111 · Cited by 216
Mozell, R. L., & McMorris, F. A. (1991) · Journal of Neuroscience Research · doi:10.1002/jnr.490300214 · Cited by 170
Cited by
Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer’s disease
Cai, Z., Hussain, M. D., & Yan, L.-J. (2014) · International Journal of Neuroscience · doi:10.3109/00207454.2013.833510 · Cited by 583
The blood–spinal cord barrier: Morphology and Clinical Implications
Bartanusz, V., Jezova, D., Alajajian, B., & Digicaylioglu, M. (2011) · Annals of Neurology · doi:10.1002/ana.22421 · Cited by 481
The role of the insulin-like growth factors in the central nervous system
D’Ercole, A. J., Ye, P., Calikoglu, A. S., & Gutierrez-Ospina, G. (1996) · Molecular Neurobiology · doi:10.1007/bf02740625 · Cited by 447
Human conditions of insulin-like growth factor-I (IGF-I) deficiency
Puche, J. E., & Castilla-Cortázar, I. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-224 · Cited by 268
Insulin-Like Growth Factor-1 Inhibits Mature Oligodendrocyte Apoptosis during Primary Demyelination
Mason, J. L., Ye, P., Suzuki, K., D'Ercole, A. J., & Matsushima, G. K. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-15-05703.2000 · Cited by 237
Metadata
- Authors
- Liu, X., Yao, D.-L., & Webster, H. F.
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 1995-04
- Volume
- 1
- Issue
- 1
- Pages
- 2-9
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W1799419079
- Cited by
- 107
- References
- 4
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insulin-like growth factor I treatment reduces clinical deficits and lesion severity in acute demyelinating experimental autoimmune encephalomyelitis. https://app.cochat.ai/papers/10.1177/135245859500100102
- The paper
- Liu, X., Yao, D.-L., & Webster, H. F. (1995). Insulin-like growth factor I treatment reduces clinical deficits and lesion severity in acute demyelinating experimental autoimmune encephalomyelitis. Multiple Sclerosis Journal. https://doi.org/10.1177/135245859500100102
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.